Bringing you the gold standard of laboratory testing to every patient’s point-of-needs.
Providing real-time PCR results in 20 minutes from sample to results, anywhere.
Enabling rapid clinical decision-making through data management and triage at the Point-of-Care testing.
Making better and faster informed decisions
Accelerate diagnostics turnaround time at a fraction of the cost
Turning informed decisions into empowering people
Diagnostics with rapid and uncompromising accuracy
Turning informed decisions into empowering people
Diagnostics with rapid and uncompromising accuracy
Providing advanced medical technology for all
Redefining healthcare for human clinical management
Laboratory Professional
Healthcare
Provider
Health System Administrator
ABOUT CREDO DIAGNOSTICS
Knowledge Empowering People
Since 2011, Credo Diagnostics has been dedicated to researching and developing revolutionary diagnostic technologies. We have created, manufactured, and commercialized accurate, rapid, and affordable molecular diagnostic solutions for point-of-care testing.
OUR REACH
Making a positive impact on the lives of billions of people around the globe
LATEST
Media News & Product Updates Keep Abreast with the Latest
Credo Preps MDx System, Multiplex Respiratory Test for US Launch
NEW YORK – Singapore-based Credo Diagnostics Biomedical is preparing to start US clinical trials fora new near-patient point-of-care molecular diagnostic system and multiplex respiratory test. The company
Credo VitaPCR™ System Has Passed the CAP Proficiency Testing
Credo Diagnostics Biomedical Pte. Ltd. to uphold quality and demonstrate product performance as well as compare it with competing brands in the market. Our VitaPCR™ system has
Miniaturized Real-Time PCR systems for SARS-CoV-2 detection at the Point-of-Care
VitaPCR™ RT-PCR test reaches sensitivity and specificity close to 100% (99,3% and 94,7%, respectively). With this 1.2 kg device, the test is simple and fast,
Comparative practicability and analytical performances of Credo VitaPCR™ Flu A&B and Cepheid Xpert® Xpress Flu/RSV platforms
We herein compared the practicability and analytical performances of VitaPCR™ Flu A&B Assay and Xpert® Xpress Flu/RSV assay, two rapid POC NAATs, by reference to
Update on the Detection of the latest SARS-CoV-2 Variant
The Level of Action: Green Green border means the letter is for information only. Singapore, September 24, 2024 – Update on the Detection of the
Update on Detection of Existing Influenza A Variant
The Level of Action: Green Green border means the letter is for information only. Singapore, June 12, 2024 – Update on Detection of Existing Influenza
Update on Detection of Existing Influenza A Variant
Singapore, December 6, 2023 – Update on the Detection of Existing Influenza A Variant Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring
Update on Detection of the Latest SARS-CoV-2 Variant BA.2.86
Singapore, September 7, 2023 – Update on Detection of the Latest SARS-CoV-2 Variant Credo Diagnostics Biomedical Pte Ltd is committed to the post-market monitoring of
